The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...
In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.
Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.
Medical Xpress on MSN8d
Why is there an increase in lung cancer among women who have never smoked?Lung cancer cases are increasing in people who have never smoked, especially in women, a new study by the World Health ...
TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
Hosted on MSN22d
The TP53 Gene and Its Role in CancerThe TP53 gene is a gene that is mutated in many cancers. It is the most common gene mutation found in cancer cells. A tumor-suppressor gene, TP53 codes for a protein that inhibits the development ...
While genetic screening is not a magic bullet, it has the potential to change the landscape of childhood cancer care in India ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback